AGAMREE® Approval with Catalyst Pharmaceuticals, Inc.

JavaScript isn't enabled in your browser, so this file can't be opened. Enable and reload.

Please join PPMD and Catalyst Pharmaceuticals for a community webinar on Wednesday, November 15th at 1:00 PM ET to discuss AGAMREE® (vamorolone) oral suspension, a new FDA-approved novel corticosteroid indicated for individuals age 2 years and older diagnosed with Duchenne muscular dystrophy. Catalyst Pharmaceuticals, the drug company commercializing AGAMREE in the US, will provide an overview of the drug, its approved label, and its patient services program supporting AGAMREE.

Please use this form to submit questions in advance.

Name *

Email *

Question *

Submit

Clear form

Never submit passwords through Google Forms.

This form was created inside of Parent Project Muscular Dystrophy. Report Abuse

Forms